Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Abstract Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission tomography (PET) may identify those pati...

Descrición completa

Detalles Bibliográficos

Principais autores:	E. A. van de Stadt, M. Yaqub, A. A. Lammertsma, A. J. Poot, P. R. Schober, R. C. Schuit, E. F. Smit, I. Bahce, N. H. Hendrikse
Formato:	Artigo
Idioma:	Inglês
Publicado:	SpringerOpen 2020-08-01
Series:	EJNMMI Research
Assuntos:	[18F] Afatinib NSCLC EGFR TKI PET/CT Targeted therapy Lung cancer
Acceso en liña:	http://link.springer.com/article/10.1186/s13550-020-00684-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!